Talquetamab plus Teclistamab in Relapsed or Refractory Multiple MyelomaYaël C. Cohen, María‐Victoria Mateos, Kihyun Kım et al.|New England Journal of Medicine|2025Cited by 96
First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Yaël C. Cohen, Hila Magen, Daniel Morillo et al.|Journal of Clinical Oncology|2023Cited by 88